Company Overview

iBio, Inc. (NYSE MKT: IBIO), a leader in the plant-made pharmaceutical field, develops and offers pharmaceutical product applications using its iBio Technology platform.

The iBio Technology platform is a proprietary, transformative technology for the production of biologics including monoclonal antibodies, other therapeutic proteins and vaccines.

Latest Financial Results

Q3 2020

Quarter Ended Mar 31, 2020

Latest Annual Filing

Fiscal Year Ended Jun 30, 2019

View Filing

Stock Information


Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information


iBio Inc.
600 Madison Avenue
Suite 1601
New York, NY 10022
T: 302-355-9452

Investor Relations

Stephen Kilmer
T: 646-274-3580

Transfer Agent

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004
T: 212-509-4000